In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides.
about
Punica granatum (Pomegranate) juice provides an HIV-1 entry inhibitor and candidate topical microbicideA series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicidesNitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophoreMicrobicides: a new hope for HIV preventionPotent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-PolMicrobicides and other topical agents in the prevention of HIV and sexually transmitted infections.A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infectionsThe importance of the vaginal delivery route for antiretrovirals in HIV prevention.Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoringIncreased Dapivirine tissue accumulation through vaginal film codelivery of dapivirine and Tenofovir.Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection3-hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1Persistent interactions between biguanide-based compound NB325 and CXCR4 result in prolonged inhibition of human immunodeficiency virus type 1 infection.The development and validation of an UHPLC-MS/MS method for the rapid quantification of the antiretroviral agent dapivirine in human plasmaThe nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cellsIn vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirinesiRNA-based topical microbicides targeting sexually transmitted infections.Clinical utility of current NNRTIs and perspectives of new agents in this class under development.UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal applicationPharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 PreventionVaginal rings for delivery of HIV microbicides.Emerging reverse transcriptase inhibitors for the treatment of HIV infection in adults.Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days.Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase.Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection.The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemicsComparative evaluation of virus transmission inhibition by dual-acting pyrimidinedione microbicides using the microbicide transmission and sterilization assayVaginal microbicides and the prevention of HIV transmissionInhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitorVaginal drug delivery systems for HIV prevention.Reverse transcriptase inhibitors as potential colorectal microbicides.Dissimilarities in the metabolism of antiretroviral drugs used in HIV pre-exposure prophylaxis in colon and vagina tissues.Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS.RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models.Pharmaceutical development of microbicide drug products.Nanoparticle-based vaginal drug delivery systems for HIV prevention.Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 InfectionMIV-150-containing intravaginal rings protect macaque vaginal explants against SHIV-RT infection.
P2860
Q24559813-CB6FF6E9-409B-46A1-AA44-EE55D249DC76Q24563844-4E49BA29-3B45-45AE-AC68-D5EBCFE38B0AQ24569706-1D19D543-E9BA-4140-8E23-EF6DF27A38E5Q27022779-F61391FE-C50F-4A21-BE17-63B1C9D087A7Q28469069-C379BF87-AB0E-45AA-8E1D-B870E8C263D2Q30359545-4A497FAA-2339-4C76-9B62-1AE7940AE1F7Q30369008-146E30A6-D660-4063-A80E-6CF523283614Q30414890-D7B50DC3-37C3-48D5-9D02-D08B376F633FQ33303221-B1D222A7-6B2D-422D-B4EE-270158FDB101Q33598736-B03B499D-F689-49BA-9DBA-C30DDBF7A638Q33770052-DC048E6D-772E-42D1-8A56-EE1F0FD2F95FQ33826278-E3B1C664-7354-417D-A14D-847F13E75917Q33826304-1CC9ED8B-6D0E-4429-8E3D-AE5532B7F2EAQ33923694-75241421-C1A6-41C5-B48D-FC188788EE02Q33930525-7A732143-5F13-41CE-A986-F9B563FAD9E0Q34647446-892426AD-2285-4F38-9A1A-93AD246A5FFAQ34737547-F2FF71D4-5DC9-451C-B06A-638FF498F8FCQ35689311-813A46EC-159D-43DD-96DE-EAFFAEA1C191Q35766254-A2CAA1CA-71F0-49E8-A6C3-D7E258C8ECBBQ35842270-F00863D9-DDD0-4FA6-A118-0A9C90A0EFABQ36086344-86344205-6696-47CE-8BE1-D5DF88B30C35Q36143276-5D40DC95-297B-4A12-959E-6CF6E846D642Q36429890-ECBAA25A-23C2-41D5-869E-9BE6CF7E00FBQ36458398-A77E3D06-BB62-40C2-8050-77DAE93B1313Q36482710-695D4D6E-B80C-423E-9712-59F6DE57AE52Q36632128-1F2D210E-7199-49E1-A930-A79DE1451F56Q36744775-6282F919-B96B-4348-908D-222C06B31B55Q36749580-738C7F7D-5264-4F6D-B7DF-A3601F215BA0Q36803970-88E6AFCB-C1F2-4C09-AC16-73027CADD279Q37063819-BC3AC3CB-E952-4967-92A0-B56EC1B54AC7Q37072072-F6B3EEE2-875A-4AA2-BDC2-A36FF2FBFA61Q37149107-1015EE42-B1B8-4D6D-9684-A17B32A59501Q37190754-5147784F-EDC6-4889-9A26-710C53CCA1F4Q37253552-5B5D61A0-6316-4138-8188-0C056774E84AQ37255082-538771B6-4635-445B-8D4C-8FD90E97541FQ37428359-8EFF8598-DBA0-4252-B76D-3CE2876F23C9Q37657468-A875FF77-5855-46B7-B3D0-1981C198C46CQ37657512-DBB03DC1-D3E1-447A-AECA-D1C99C704DA7Q37705969-4D3E1B41-4E11-43BA-A9F9-69CCA4B524D6Q37713059-D1323AB2-0C11-42DB-BAF2-4CCEA5BCCF80
P2860
In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
In vitro evaluation of nonnucl ...... deficiency virus microbicides.
@ast
In vitro evaluation of nonnucl ...... deficiency virus microbicides.
@en
type
label
In vitro evaluation of nonnucl ...... deficiency virus microbicides.
@ast
In vitro evaluation of nonnucl ...... deficiency virus microbicides.
@en
prefLabel
In vitro evaluation of nonnucl ...... deficiency virus microbicides.
@ast
In vitro evaluation of nonnucl ...... deficiency virus microbicides.
@en
P2093
P2860
P1476
In vitro evaluation of nonnucl ...... deficiency virus microbicides.
@en
P2093
Guido Vanham
Jens Van Roey
Jo Michiels
Katrien Fransen
Luc Kestens
Paul Janssen
Yven Van Herrewege
P2860
P304
P356
10.1128/AAC.48.1.337-339.2004
P407
P577
2004-01-01T00:00:00Z